Survival Outcomes of Patients With Borderline Resectable and Resectable Pancreatic Adenocarcinoma Treated With Neoadjuvant Short-Course Chemoradiotherapy With Capecitabine-Based vs. Gemcitabine-Based Concurrent Chemotherapy

被引：0
|
作者：
Neibart, S. S. [1 ]
Mamidanna, S. [1 ]
Chundury, A. [1 ]
Sayan, M. [1 ]
Alexander, H. R. [2 ]
August, D. [2 ]
Berim, L. D. [3 ]
Boland, P. M. [3 ]
Grandhi, M. S.
Gulhati, P. [3 ]
Hochster, H. S. [3 ]
Kennedy, T. J. [2 ]
Langan, R. C. [2 ]
Spencer, K. [3 ]
Jabbour, S. K. [1 ]
机构：
[1] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA
[2] Rutgers Canc Inst New Jersey, Dept Surg Oncol, New Brunswick, NJ USA
[3] Rutgers Canc Inst New Jersey, Dept Med Oncol, New Brunswick, NJ USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2081
引用
收藏
页码：E64 / E64
页数：1
相关论文
共 50 条
  • [1] Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy
    Neibart, Shane S.
    Mamidanna, Swati
    Chundury, Anupama
    Sayan, Mutlay
    Alexander, H. Richard
    August, David A.
    Berim, Lyudmyla D.
    Boland, Patrick M.
    Grandhi, Miral S.
    Gulhati, Prateek
    Hochster, Howard S.
    Langan, Russell C.
    Spencer, Kristen R.
    Kennedy, Timothy J.
    Deek, Matthew P.
    Jabbour, Salma K.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (06) : 2557 - +
  • [2] Neoadjuvant Gemcitabine-based Accelerated Hyperfractionation Chemoradiotherapy for Patients with Borderline Resectable Pancreatic Adenocarcinoma
    Takeda, Yutaka
    Nakamori, Shoji
    Eguchi, Hidetoshi
    Kobayashi, Shogo
    Marubashi, Shigeru
    Tanemura, Masahiro
    Konishi, Koji
    Yoshioka, Yasuo
    Umeshita, Koji
    Mori, Masaki
    Doki, Yuichiro
    Nagano, Hiroaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (12) : 1172 - 1180
  • [3] Gemcitabine-Based Chemoradiotherapy Followed by Surgery for Borderline Resectable and Locally Unresectable Pancreatic Ductal Adenocarcinoma
    Kobayashi, Motoyuki
    Mizuno, Shugo
    Murata, Yasuhiro
    Kishiwada, Masashi
    Usui, Masanobu
    Sakurai, Hiroyuki
    Tabata, Masami
    Ii, Noriko
    Yamakado, Koichiro
    Inoue, Hiroyuki
    Shiraishi, Taizo
    Yamada, Tomomi
    Isaji, Shuji
    PANCREAS, 2014, 43 (03) : 350 - 360
  • [4] Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer
    Cho, In Rae
    Chung, Moon Jae
    Bang, Seungmin
    Park, Seung Woo
    Chung, Jae Bock
    Song, Si Young
    Seong, Jinsil
    Hwang, Ho Kyoung
    Kang, Chang Moo
    Lee, Woo Jung
    Park, Jeong Youp
    PANCREATOLOGY, 2013, 13 (05) : 539 - 543
  • [5] Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial
    Koerkamp, B. Groot
    Janssen, Q. P.
    van Dam, J. L.
    Bonsing, B. A.
    Bos, H.
    Bosscha, K. P.
    Haberkorn, B. C. M.
    de Hingh, I. H. J. T.
    Karsten, T. M.
    Van der Kolk, M. B.
    Liem, M. S. L.
    Loosveld, O. J. L.
    Patijn, G. A.
    van Santvoort, H. C. M.
    de Vos-Geelen, J.
    van der Holt, B.
    Homs, M. Y. V.
    van Tienhoven, G.
    Besselink, M. G.
    Wilmink, H. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1323 - S1323
  • [6] Oncologic Outcomes of Patients with Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Gemcitabine-Based Chemoradiation: A 10-Year Experience
    Louie, R. J.
    Hill, M. V.
    Liu, S. J.
    Caba-Molina, D.
    Judkins, J. J.
    Zaki, B. I.
    Shatzel, J. J.
    Mody, K.
    Pipas, J. M.
    Hourdequin, K. C.
    Ripple, G. H.
    Tsongalis, G. H.
    Tsapakos, M. J.
    Mills, J. B.
    Lisovsky, M.
    Suriawinata, A. A.
    Angeles, C. V.
    Colacchio, T. A.
    Sutton, J. E., Jr.
    Gordon, S. R.
    Gardner, T. B.
    Barth, R. J., Jr.
    Smith, K. D.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S167 - S167
  • [7] Efficacy and toxicity results of neoadjuvant gemcitabine-based combined chemoradiotherapy in patients with borderline resectable pancreatic adenocarcinoma: A single-institution experience
    Diaz Beveridge, R.
    Garcia-Mora, C.
    Moya, A.
    Bruixola, G.
    Aparicio, J.
    Reche, E.
    Segura, A.
    Caballero, J.
    Gimenez, A.
    Bennis, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S591 - S591
  • [8] Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer-Current Status and Future Perspectives
    Labori, Knut Jorgen
    FRONTIERS IN SURGERY, 2022, 9
  • [9] Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
    Yoo, Changhoon
    Kang, Jihoon
    Kim, Kyu-Pyo
    Lee, Jae-Lyun
    Ryoo, Baek-Yeol
    Chang, Heung-Moon
    Lee, Sang Soo
    Park, Do Hyun
    Song, Tae Jun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Park, Jin-Hong
    Hwang, Dae Wook
    Song, Ki Byung
    Lee, Jae Hoon
    Kim, Song Cheol
    ONCOTARGET, 2017, 8 (28) : 46337 - 46347
  • [10] Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
    Evans, Douglas B.
    Varadhachary, Gauri R.
    Crane, Christopher H.
    Sun, Charlotte C.
    Lee, Jeffrey E.
    Pisters, Peter W. T.
    Vauthey, Jean-Nicolas
    Wang, Huamin
    Cleary, Karen R.
    Staerkel, Gregg A.
    Charnsangavej, Chusilp
    Lano, Elizabeth A.
    Ho, Linus
    Lenzi, Renato
    Abbruzzese, James L.
    Wolff, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3496 - 3502
12345